Nuclear Pharmacy
Fred P. Gattas 6-1. Key Points ■ Radiopharmaceuticals are mainly used for diagnostic purposes, but can also be used for palliative and therapeutic indications. ■ Technetium Tc-99m is eluted from…
Galantamine for Alzheimer’s Disease and Alzheimer’s Disease with Cerebrovascular Disease
(1) New York, New York, USA 3.1 Introduction Despite numerous attempts to develop new classes of compounds for either the progression or symptomatic treatment of Alzheimer’s disease, there have…
Basic Theory of Pharmacology for Alzheimer’s Disease
(1) Toyonaka, Japan 1.1 From the First Report of Alzheimer’s Disease to Its Establishment as a Concept An illness, later to be named Alzheimer’s disease (AD), was first reported…
How Do We Use Symptomatic Drugs to Treat Dementia?
(1) Toyonaka, Japan 6.1 Introduction Symptomatic drugs for Alzheimer’s disease (AD) target neurotransmitters. The cholinergic nervous system is closely involved in memory and learning. The AD brain shows a…
The Practical Pharmacology of Donepezil
(1) Toyonaka, Japan 2.1 Introduction From 1976 to 1977, three British groups established the acetylcholine (ACh) hypothesis, which claims that the activity of choline acetyltransferase (ChAT), an ACh synthase,…
Practical Pharmacology of Rivastigmine
, Ignacio Flores2 and Roser Ribosa-Nogué3 (1) Barcelona, Spain (2) Servicio de Neurología, Hospital San Martín, La Plata, Buenos Aires, Argentina (3) Unitat de Memòria, Servei de Neurologia, Hospital de la Santa…
Practical Pharmacology of Memantine
(1) Southhampton, United Kingdom 5.1 Introduction Memantine is a noncompetitive, voltage-dependent N-methyl-D-aspartate (NMDA) receptor antagonist. It is licensed for the treatment of moderate to severe AD in the USA…
Drug Antagonism
Orthosteric Drug Effects Outline Bi-Molecular Systems51 New Terminology52 What is Drug Antagonism?53 Antagonist Potency53 Mechanism(s) of Receptor Antagonism54 Orthosteric (Competitive and Non-Competitive) Antagonism56 Slow Dissociation Kinetics and Non-Competitive Antagonism62 Partial…
